Skip to main
ELV

ELV Stock Forecast & Price Target

ELV Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Elevance Health is maintaining its strong position as a leader in the health insurance industry with its unique role as the largest single provider of Blue Cross Blue Shield branded coverage and its expansion into new markets through acquisitions. The company is also diversifying with growth opportunities in pharmacy benefit management and other healthcare services. Despite potential risks, such as Medicaid cost spikes and adverse selection, Elevance's careful capital deployment, strong balance sheet, and commitment to returning to >12% EPS growth in 2027+ make it an attractive investment opportunity with potential for continued margin expansion and increased profitability in the coming years.

Bears say

Elevance Health is facing several challenges in the upcoming years, including declining membership in Medicare Advantage and Medicaid plans, misalignment between rates and acuity, and potential market exits. These factors will likely result in pressure on margins and may hinder the company's ability to meet its 12% EPS growth target for 2027. The company's investments in AI/tech adoption and Carelon scalability may also create a significant SG&A headwind to EPS in the coming years. Additionally, the risk of unexpected ACA risk pool deterioration, Medicaid cost increases, an elongated turnaround for MA, and erratic pricing cycles could further impact the company's financial performance.

ELV has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elevance Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elevance Health Inc (ELV) Forecast

Analysts have given ELV a Buy based on their latest research and market trends.

According to 18 analysts, ELV has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $383.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $383.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elevance Health Inc (ELV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.